Innovus Pharma Announces the Launch of Its Product AllerVarx™ in Canada for Allergic Rhinitis

Published: Jun 06, 2018

SAN DIEGO--(BUSINESS WIRE)-- Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women's health and respiratory diseases, today announced the launch of its product AllerVarx™, which is a clinically proven, Natural Health Product approved by Health Canada to help reduce symptoms of allergic rhinitis such as nasal discharge, sneezing, nasal congestion and itching. Innovus Pharma launched AllerVarx™ in Canada through the Company’s website and its Canadian Beyond Human™ marketing and sales platform.

“We are happy to announce the launch of AllerVarx™ in Canada,” said Dr. Bassam Damaj, the President and Chief Executive Officer of Innovus Pharma. “We believe the product will sell well there for customers with allergic rhinitis and represents the fifth product launched through our own sales and marketing commercial efforts in Canada in addition to ProtaGoRx™, Vesele®, Apeaz® and Xyralid® and is our ninth product on the Canadian market including Zestra®, Zestra Glide® and Uxor™ (EjectDelay™) marketed by Orimed Pharma and UriVarx® through our partnership with Acerus Pharmaceuticals Corporation. We have been experiencing a much higher return on our ads in Canada and we expect the Canadian market to grow and become a more significant source of revenue for the Company,” continued Dr. Damaj.

About AllerVarx™

AllerVarx™ is a Natural Health Product approved by Health Canada (NPN # 80082649) to help reduce symptoms of allergic rhinitis such as nasal discharge, sneezing, nasal congestion and itching. It is a patented formulation produced in bilayer tablets with a technology that allows a controlled release of the ingredients. The fast-release layer allows the rapid antihistaminic activity of Perilla. The sustained-release layer enhances Quercetin and Vitamin D3 bioavailability, thanks to its lipidic matrix, and exerts anti-allergic activity spread over time. For more information on the product please visit www.allervarx.com.

AllerVarx™, sold in Europe under the brand name Lertal®, is a product the Company exclusively in-licensed for the U.S. and Canada from NTC s.r.l., an Italian company, and is a patented formulation produced in bilayer tablets with a technology that allows a controlled release of the ingredients. The fast-release layer allows the rapid antihistaminic activity of Perilla. The sustained-release layer enhances Quercetin and Vitamin D3 bioavailability, thanks to its lipidic matrix, and exerts anti-allergic activity spread over time.

AllerVarx™ was studied in a published clinical trial assessing the reduction of both nasal and ocular symptoms in allergic patients, and daily consumption of anti-allergic drugs, over a period of 30 days. AllerVarx™ showed a reduction of approximately 70% in total symptom scores and a reduction of approximately 73% in the use of anti-allergic drugs. There were no side effects noted during the administration of AllerVarx™ and all the patients enrolled finished the study with good compliance.

The World Health Organization (“WHO”) classifies allergies as the fourth most important chronic disease in the world. Allergic Rhinitis (“AR”) is the most common form of non-infectious rhinitis, affecting between 10% and 30% of all adults in the United States, and as many as 40% of U.S. children. Epidemiologic studies show that the prevalence of AR is expected to still be important in the next decades. The World Allergy Organization (“WAO”) has estimated that 400 million people in the world suffer from AR, which remains to a large extent underdiagnosed and undertreated.

About Innovus Pharmaceuticals, Inc.

Headquartered in San Diego, Innovus Pharma is an emerging OTC consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. Innovus Pharma delivers innovative and uniquely presented and packaged health solutions through its (a) OTC medicines and consumer and health products, which we market directly, (b) commercial partners to primary care physicians, urologists, gynecologists and therapists, and (c) directly to consumers through our on-line channels, retailers and wholesalers. The Company is dedicated to being a leader in developing and marketing new OTC and branded Abbreviated New Drug Application (“ANDA”) products. The Company is actively pursuing opportunities where existing prescription drugs have recently, or are expected to, change from prescription (or Rx) to OTC.

For more information, go to www.innovuspharma.com; www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.urivarx.com; www.sensumplus.com; www.myandroferti.com; www.beyondhumantestosterone.com; www.getbeyondhuman.com; www.trybeyondhuman.com; www.recalmax.com; www.prostagorx.com; www.fluticare.com; www.allervarx.com; www.apeaz.com; and www.diabasens.com.

Innovus Pharma's Forward-Looking Safe Harbor:

Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, projected revenues from the AllerVarx™ product in Canada, estimated market for its products, and statements about achieving its other development, growth, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent filing on Form S-1, annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.

 

Contacts

Innovus Pharma Investor Relations
Randy Berholtz, +1 858-249-7865
ir@innovuspharma.com

 
 

Source: Innovus Pharmaceuticals, Inc.

Back to news